At the time of writing, Spero Therapeutics Inc [SPRO] stock is trading at $2.85, up 3.26%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SPRO shares have gain 7.95% over the last week, with a monthly amount glided 359.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spero Therapeutics Inc [NASDAQ: SPRO] stock has seen the most recent analyst activity on December 20, 2024, when Evercore ISI downgraded its rating to a In-line but kept the price target unchanged to $5 for it. Previously, Evercore ISI upgraded its rating to Outperform on September 23, 2022, and elevated its price target to $8. On October 01, 2021, downgrade downgraded it’s rating to Perform. H.C. Wainwright reiterated its Buy rating and increased its price target to $40 on January 22, 2021. Berenberg initiated its recommendation with a Buy and recommended $47 as its price target on December 16, 2020. In a note dated November 05, 2019, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $28 to $35.
For the past year, the stock price of Spero Therapeutics Inc fluctuated between $0.51 and $2.95. Spero Therapeutics Inc [NASDAQ: SPRO] shares were valued at $2.85 at the most recent close of the market.
Analyzing the SPRO fundamentals
According to Spero Therapeutics Inc [NASDAQ:SPRO], the company’s sales were 28.30M for trailing twelve months, which represents an 21.57% jump. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -1.61%, and Net Profit Margin reading is -1.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.99 and Total Capital is -1.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Spero Therapeutics Inc [NASDAQ:SPRO] has a current ratio of 2.56. As well, the Quick Ratio is 2.56, while the Cash Ratio is 1.68. Considering the valuation of this stock, the price to sales ratio is 5.63, the price to book ratio is 4.71.
Transactions by insiders
Recent insider trading involved Keutzer Timothy, Chief Operating Officer, that happened on Feb 05 ’25 when 56537.0 shares were sold. CFO & CBO, Rajavelu Esther completed a deal on Feb 05 ’25 to sell 20689.0 shares. Meanwhile, CEO & President Shukla Sath sold 0.16 million shares on Feb 05 ’25.
